Payment of clinical research subjects.
Offering payment to clinical research subjects, in an effort to enhance recruitment by providing an incentive to take part or enabling subjects to participate without financial sacrifice, is a common yet uneven and contentious practice in the US. Concern exists regarding the potential for payment to unduly influence participation and thus obscure risks, impair judgment, or encourage misrepresentation. Heightening these concerns is the participation not only of adults but also of children in pediatric research trials. Thorough assessment of risks, careful eligibility screening, and attention to a participant's freedom to refuse all serve to reduce the possibility of compensation adversely affecting the individual and/or the study. Institutional review boards currently evaluate payment proposals with minimal guidance from federal regulations. Here, reasons for providing payment, payment models, ethical concerns, and areas for further research are examined.
Grady
Christine
C
Department of Clinical Bioethics, Clinical Center, NIH, Bethesda, MD, USA. cgrady@nih.gov
D000328:Adult; D035843:Biomedical Research / Q000191:economics; D002648:Child; D006304:Health Status; D006801:Humans; D018803:Models, Economic; D018579:Patient Selection / Q000941:ethics*; D035842:Research Subjects / Q000191:economics*; D014481:United States